A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 261 participants.
Also called NCT04736628
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 261 participants
- Sponsor
- Registry
-
NCT04736628 -
2020-002930-33
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Canada, China, Denmark, Germany, Hong Kong SAR China, Japan, Malaysia, Mexico, New Zealand, Poland, Portugal, Russia, Spain, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04736628. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-27 (actual); primary completion 2023-08-15 (actual). Results posted on 2024-09-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Avenciguat
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct04736628- Content hash
832a358f83f3b6f194110dd41f9c12f01cbcb2b9a6b62373776978f4a8317490